Genmab A/S has raised its forecast for revenue and operating profit in 2022 after seeing a sharp increase in royalty income in the first half from Darzalex (daratumumab), a CD38 monoclonal antibody for multiple myeloma. Revenue is now expected to be between DKK 12,000 to 13,000 million and operating profit between DKK 3,800 to 5,400 million. In 2021, revenue was DKK 8,482 million (€1,140 million) and operating profit was DKK 3,018 million.
The US Food and Drug Administration has extended a clinical hold on a proposed Phase 3 clinical trial of a microbiome-based therapeutic developed by MaaT Pharma SA of France because it requires more information about the composition of the faecal-derived product. MaaT Pharma announced the clinical hold extension on 10 August.
Evotec SE increased revenue and expanded its drug discovery and development alliances in the first half of 2022 even as some sectors of the pharma industry experienced a slowdown. Group revenue was €336.9 million, up by 24% from a year earlier. More than three quarters of group revenue, or €258.8 million, was generated by the company’s fee-for-service business while €78 million came from partnered drug discovery.
Corporate Strategy
The microbiome and cancer
Interview with Hervé Affagard
Drug Discovery
Small molecules make a comeback
By Nick Ray
Commentary
Investigating a functional cure
for hepatitis B
By Thomas Evans
Research Strategy
Oral microbiota provides
new clue to brain disorders
Stock Market Performance
Stocks plummet in Q2 but
biotech keeps innovating
Regulation
Green light for haemophilia A
gene therapy in Europe
Company News
Enterome partners with Nestlé
Agomab secures new funding
